TY - JOUR
T1 - Post-acute sequelae of COVID-19 in a non-hospitalized cohort
T2 - Results from the Arizona CoVHORT
AU - Bell, Melanie L.
AU - Catalfamo, Collin J.
AU - Farland, Leslie V.
AU - Ernst, Kacey C.
AU - Jacobs, Elizabeth T.
AU - Klimentidis, Yann C.
AU - Jehn, Megan
AU - Pogreba-Brown, Kristen
N1 - Publisher Copyright:
Copyright: © 2021 Bell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/8
Y1 - 2021/8
N2 - Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of PASC, defined as experiencing at least one symptom 30 days or longer, and prevalence of individual symptoms. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30–250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95% confidence interval: 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress/anxiety (30.8%). The median number of symptoms was 3 (range 1–20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%.
AB - Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of PASC, defined as experiencing at least one symptom 30 days or longer, and prevalence of individual symptoms. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30–250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95% confidence interval: 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress/anxiety (30.8%). The median number of symptoms was 3 (range 1–20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%.
UR - http://www.scopus.com/inward/record.url?scp=85112001068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112001068&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0254347
DO - 10.1371/journal.pone.0254347
M3 - Article
C2 - 34347785
AN - SCOPUS:85112001068
SN - 1932-6203
VL - 16
JO - PloS one
JF - PloS one
IS - 8 August
M1 - e0254347
ER -